Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: opalapril who wrote (6994)	8/26/1998 12:58:00 PM
From: Kushi Kullar	Read Replies (2) \| Respond to of 17367

This apparent exodus from XOMA certainly does not look good. Is there a way to determine if these are net adds or if they are replacements?

To: opalapril who wrote (6994)	8/26/1998 1:52:00 PM
From: aknahow	Read Replies (1) \| Respond to of 17367

Opala, call Ellen Martin, if you have not done so. Some are replacements and some are new. By calling you will have the correct information on which to make any decision you choose. I will miss you, if and when you sell and no longer post. The price action of many biotechs has been terrible but that does not make the decline in XOMA any less painful. I think biotechs are a sector that should eventually attract interest. As, posted elsewhere I am concerned about how this particular industry can continue to raise capital when general equity markets are weak. The terms agreed to in even strong markets were harsh. As long as the FDA continues to insist on more than just safety trial will remain very costly. Unmet demand for capital will probably lead to failures, consolidations, and buyouts. I do not see any hope that the FDA will make any radical changes, for at least the next ten years. California and other biotech states will risk seeing their biotech industries decimated. Wonder if the Libertarians will ever win enough positions of power to have any impact.